ADAM proteins as therapeutic targets in loosening of total hip replacement implants?

Journal of Rheumatology

Volumn 32, Issue 10, 2005, Pages 1870-1872

  Naus, Silvia ^a   Bartsch, Jörg Walter ^b  

^a BIELEFELD UNIVERSITY   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DISINTEGRIN; METALLOPROTEINASE; METALLOPROTEINASE ADAM; METALLOPROTEINASE ADAM 12; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; EDITORIAL; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; IMPLANT; INFLAMMATION; MONOCYTE; MONONUCLEAR CELL; MYOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROSTHESIS FAILURE; PROSTHESIS LOOSENING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; TOTAL HIP PROSTHESIS;

ADAM PROTEINS; ARTHROPLASTY, REPLACEMENT, HIP; ENZYME INHIBITORS; HUMANS; OSTEOLYSIS; PROSTHESIS FAILURE;

EID: 26444476450     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (19)

1. Wolfsberg TG, Straight PD, Gerena RL. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev Biol 1995;169:378-83.
2. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17:7-30.
3. Moss ML, Bartsch JW. Therapeutic benefits from targeting of ADAM family members. Biochemistry 2004;43:7227-35.
4. Ma G, Ainola M, Santavirta S, et al. Increased expression and processing of ADAM 12 (meltrin-alpha) in osteolysis associated with aseptic loosening of total hip replacement implants. J Rheumatol 2005;32:1943.
5. Goldring SR, Jasty M, Roelke MS, Rourke CM, Bringhurst FR, Harris WH. Formation of a synovial-like membrane at the bone-cement interface. Its role in bone resorption and implant loosening after total hip replacement. Arthritis Rheum 1986;29:836-42.
6. Gallo J, Kaminek P, Ticha V, Rihakova P, Ditmar R. Formation of a synovial-like membrane at the bone-cement interface. Its role in bone resorption and implant loosening after total hip replacement. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2002;146:21-8.
7. Schwarz EM, Looney RJ, O'Keefe RJ. Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis. Arthritis Res 2000;2:165-8.
8. Yagami-Hiromasa T, Sato T, Kurisaki T, Kamijo K, Nabeshima Y, Fujisawa-Sehara A. A metalloprotease-disintegrin participating in myoblast fusion. Nature 1995;377:652-6.
9. Lafuste P, Sonnet C, Chazaud B, et al. ADAM12 and alpha 9 beta 1 integrin are instrumental in human myogenic cell differentiation. Mol Biol Cell 2005;16:861-70.
10. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000;278:511-5.
11. Tian BL, Wen JM, Zhang M, Xie D, Xu RB, Luo CJ. The expression of ADAM12 (meltrin alpha) in human giant cell tumours of bone. Mol Pathol 2002;55:394-7.
12. Mandelin J, Li TF, Hukkanen MV, et al. Increased expression of a novel osteoclast-stimulating factor, ADAMS, in interface tissue around loosened hip prostheses. J Rheumatol 2003;30:2033-8.
13. Yoshida S, Setoguchi M, Higuchi Y, Akizuki S, Yamamoto S. Molecular cloning of cDNA encoding MS2 antigen, a novel cell surface antigen strongly expressed in murine monocytic lineage. Int Immunol 1990;2:585-91.
14. Choi SJ, Han JH, Roodman GD. ADAMS: a novel osteoclast stimulating factor. J Bone Miner Res 2001;16:814-22.
15. Schlomann U, Wildeboer D, Webster A, et al. The metalloprotease disintegrin ADAMS. Processing by autocatalysis is required for proteolytic activity and cell adhesion. J Biol Chem 2002;277:48210-9.
16. Kelly K, Hutchinson G, Nebenius-Oosthuizen D, et al. Metalloprotease- disintegrin ADAMS: expression analysis and targeted deletion in mice. Dev Dyn 2005;232:221-31.
17. Yoshiyama K, Higuchi Y, Kataoka M, Matsuura K, Yamamoto S. CD156 (human ADAMS): expression, primary amino acid sequence, and gene location. Genomics 1997;41:56-62.
18. Schlomann U, Rathke-Hartlieb S, Yamamoto S, Jockusch H, Bartsch JW. Tumor necrosis factor alpha induces a metalloprotease-disintegrin, ADAMS (CD 156): Implications for neuron-glia interactions during neurodegeneration. J Neurosci 2000;20:7964-71.
19. Schwarz EM, Lu AP, Goater JJ, et al. Tumor necrosis factor-alpha/nuclear transcription factor-kappa B signaling in periprosthetic osteolysis. J Orthop Res 2000;18:472-80.